Oral Peptide Drug Delivery: Permeation Enhancers, Enteric Coating, and 2026 Clinical Outlook

Industry Authority | 2026-07-10 | 13 min read

A 2026 industry review of oral peptide delivery: gastrointestinal barriers, permeation enhancers (SNAC, sodium caprate, bile salts), enteric coatings, oral semaglutide lessons, and clinical pipeline.

Introduction: the oral peptide challenge

Oral drug delivery is the gold standard for patient compliance. Pills are preferred over injections for chronic conditions. But oral peptide delivery is exceptionally difficult. The gastrointestinal tract has evolved to digest proteins and peptides — exactly what we want to deliver as therapeutics.

Despite these challenges, two oral peptides have reached the market: oral semaglutide (Rybelsus, 2019) and oral octreotide (Mycapssa, 2020). Their success demonstrates that oral peptide delivery is possible with the right technology.

This 2026 review covers the science behind oral peptide delivery, including gastrointestinal barriers, permeation enhancers, enteric coatings, and the clinical pipeline.

Gastrointestinal barriers to peptide absorption

Barrier 1: Gastric acidity

The stomach maintains pH 1-3 through HCl secretion. Most peptides are stable at this pH for 30-60 minutes but undergo acid-catalyzed hydrolysis at longer residence times.

Peptides particularly sensitive to acid include sequences with aspartate-rich regions (Asp-Pro cleavage sites) and glutamine-rich regions that can undergo deamidation.

Barrier 2: Proteolytic enzymes

The GI tract contains multiple proteases that degrade peptides:

| Enzyme | Location | Specificity | | --- | --- | --- | | Pepsin | Stomach (pH 1.5-2.0) | Broad, prefers aromatic residues | | Trypsin | Duodenum | Lys, Arg at C-terminal side | | Chymotrypsin | Duodenum | Aromatic residues at C-terminal side | | Elastase | Duodenum | Small uncharged residues | | Carboxypeptidases | Small intestine | C-terminal amino acid removal | | Aminopeptidases | Brush border | N-terminal amino acid removal |

Barrier 3: Mucus layer

The intestinal epithelium is covered by a 100-400 µm mucus layer that traps peptides via electrostatic interactions and slows diffusion to the epithelium.

Barrier 4: Epithelial barrier

The intestinal epithelium has tight junctions (claudins, occludin, ZO-1) that prevent paracellular transport of large polar molecules. Active efflux transporters (P-gp, BCRP) pump peptides back into the gut lumen.

Barrier 5: First-pass metabolism

After absorption, peptides enter the portal circulation and pass through the liver where hepatic proteases further degrade them.

Permeation enhancers

SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate)

SNAC is the permeation enhancer in oral semaglutide (Rybelsus). It is co-formulated with semaglutide at 300 mg SNAC per 7-14 mg semaglutide tablet.

Mechanism:

  • SNAC and semaglutide co-localize in the gastric absorption window
  • SNAC inserts into the apical membrane, creating hydrophobic domains
  • Semaglutide permeates through these domains
  • SNAC dissociates, membrane returns to normal

SNAC does not affect tight junctions or cause cell damage. It creates a transient, localized effect.

Sodium caprate (C10)

Sodium caprate is a medium-chain fatty acid salt that disrupts tight junctions transiently, enabling paracellular peptide transport. It is used in some experimental oral peptide formulations.

Bile salts

Bile salts (sodium taurocholate, sodium glycocholate) disrupt cell membranes, inhibit proteolytic enzymes, and form micelles with peptides. They are being explored in combination formulations.

Enteric coatings

Enteric coatings protect peptides from gastric acidity and proteases:

pH-sensitive polymers

| Polymer | Dissolution pH | Application | | --- | --- | --- | | Eudragit L100 | pH > 6.0 | Duodenum | | Eudragit S100 | pH > 7.0 | Jejunum/ileum | | HPMC-AS | pH 5.5-7.0 | pH-dependent |

Time-dependent coatings

Time-dependent coatings release peptide after a fixed delay, independent of pH. They are useful for colon targeting.

Oral semaglutide: a case study

Rybelsus (oral semaglutide) was approved in 2019 for type 2 diabetes. The formulation contains:

  • 3-14 mg semaglutide
  • 300 mg SNAC
  • pH-relevant excipients

Dosing instructions:

  • Take in the morning, fasting
  • Take with ≤120 mL water
  • Wait 30 minutes before eating, drinking, or taking other medications
  • Avoid grapefruit juice

Clinical efficacy (PIONEER trials):

  • HbA1c reduction: 1.0-1.5%
  • Body weight reduction: 3-5 kg
  • Comparable to injectable semaglutide at higher dose

Bioavailability: approximately 0.4-1.0%, highly variable between subjects.

Oral octreotide: Mycapssa

Mycapssa is an oral form of octreotide (a somatostatin analog) approved in 2020 for acromegaly maintenance therapy. It uses a different permeation enhancer technology (transient permeation enhancer, TPE).

Clinical pipeline

Multiple oral peptides are in development:

| Peptide | Technology | Indication | Stage | | --- | --- | --- | --- | | Oral insulin | Enteric + permeation enhancer | Diabetes | Phase 3 | | Oral GLP-1/GIP | SNAC variant | Obesity | Phase 1 | | Oral PTH | Permeation enhancer | Osteoporosis | Phase 2 | | Oral calcitonin | Enteric coating | Osteoporosis | Phase 2 |

Summary

Oral peptide delivery is one of the most challenging areas in pharmaceutical research. The success of oral semaglutide and oral octreotide demonstrates that permeation enhancer technology can overcome the GI barrier. Multiple oral peptides are in clinical development, promising to expand oral peptide therapy beyond current approved products.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalogSupplier checklistMore peptide guides